Skip to content
Review

[Novel therapeutic strategies to separate GVHD from GVL based on GVHD pathophysiology and mechanisms of leukemia relapse].

2026 · [Rinsho ketsueki] The Japanese journal of clinical hematology · Vol 67 7, pp. 819-827 · 0 citations
Medicine

TL;DR

Emerging strategies to ameliorate GVHD without attenuating GVL, including intensified local therapy, selective trafficking blockade, S1PR modulators that limit pathogenic T-cell migration, and tissue-protective agents that enhance epithelial regeneration and prevent the establishment of inflammatory memory are summarized.

View source

Similar papers

Review Open access Sep 2026

Progress in reprogramming failed graft-versus-leukemia immunity in acute myeloid leukemia relapse after allogeneic transplantation

Relapse of acute myeloid leukemia (AML) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) affects 40–50% of recipients and remains the leading cause of posttransplant mortality; median overall survival is approximately 5 months and 1-year survival is below 20%. Conventional salvage—chemotherapy, immu...

Naif I. Aljohani, Ahlam Almasari, Zayed Alzahrani et al. · 0 citations
Open access Aug 2026

CXCR4-dependent migratory differences between peripheral Tregs and Tcons preserve GvL while limiting GvHD after HSCT.

Although studies on HLA-haploidentical hematopoietic stem cells transplant (HSCT) for high-risk acute myeloid leukemia (AML) showed that regulatory and conventional T-lymphocyte (Treg/Tcon) immunotherapy prevents graft-versus-host disease (GvHD) while it exerts T-cell dependent graft-versus-leukemia (GvL) effect, its m...

L. Ruggeri, Antonio Pierini, E. Urbani et al. · 0 citations
Aug 2026

CAR-T and GvHD: Have We Engineered GvHD Out of Allogeneic CAR‑T Therapy?

A focused Perspective asks whether GvHD directed engineering has made clinically significant product-associated GvHD rare and whether allogeneic CAR-T must reduce donor-to-host alloreactivity while managing the distinct host-versus-graft barrier.

Nabeel Ahmed, Jawaria Jabeen · 0 citations
Review Aug 2026

Breaking the relapse barrier: innovative approaches to improve CAR T-cell efficacy by targeting leukemic stem cells (LSCs) and measurable residual disease (MRD) in acute myeloid leukemia.

Acute Myeloid Leukemia (AML) is biologically heterogeneous, clinically aggressive and is characterized by the uncontrolled clonal expansion of immature myeloid progenitors in the bone marrow microenvironment. Despite the achievement of remission with frontline treatments, relapse is disturbingly common and is the major...

A. Mathew, Ronak Raheja, Pranav Thomas Alex · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.